Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses AbbVie's patents on the innovator adalimumab, Humira.
Transcript:
A recent report from I-MAK said that AbbVie is one of the worst patent offenders in pharma. Why is that?
So as I said, as our study found, AbbVie is one of the worst offenders in pharma because of the number of patents it’s accumulated.
We did a report called “Overpatented, Overpriced” where we looked at the top 12 selling drugs in the United States. Of all those 12 drugs, AbbVie has the highest number of patents for its drug. On average, we found of those top 12 selling drugs, 125 patent applications on average across those drugs, and we’ve seen price increases between 2012 and 2016—at least 68% pricing increase over that period on average.
So in that sense, AbbVie has been the most egregious actor when it comes to what we would call overpatenting deliberately. I think it’s important that if you look at the time scale AbbVie filed these patents, 89% were filed after the first approval in 2002, and even more outrageously, they filed 122 of those applications after the first patent expired in 2014.
That suggests to me that this is more than what we might call “inventions” going on in the Humira space, but that these were strategic patents in order to delay competition.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.